The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration’s (FDA) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. E-mail Dr. Mancano at michael.mancano@temple.edu. Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA’s MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.
Get full access to this article
View all access options for this article.
References
1.
LeonardJBMunirKMKimHK.Metoclopramide induced pheochromocytoma crisis. Am J Emerg Med. 2018;36:1124.e1-1124.e2.
2.
Hamel SénécalLChrétienBJean-JacquesPYLelong BoulouardVCohenDLe BoisselierR.A case of drug dependence syndrome to baclofen following high-dose therapy. J Clin Psychopharmacology. 2018;38:277-279.
3.
MartinMForneckerLMMarcellinLet al. Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening. Bone Marrow Transplant. 2017;52:1674-1677.
4.
BarashJGanetskyMBoyleKet al. Acute amnestic syndrome associated with fentanyl overdose. N Engl J Med. 2018;378:1157-1158.
5.
SeegobinKBuenoEMaharajSAshbyTBrownMJonesL.Toxic epidermal necrolysis after ivermectin. Am J Emerg Med. 2018;36:887-889.
6.
Smith-CohnMGillDVoorhiesBAgarwalNGarrido-LagunaI.Case report: Pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy. 2017;9:797-804.
